Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen McCroskery

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Biorxiv : the Preprint Server for Biology|August 9, 2020
A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccineWeina Sun, Stephen McCroskery, Wen-Chun Liu, et al.
Biorxiv : the Preprint Server for Biology|March 30, 2022
Trivalent NDV-HXP-S vaccine protects against phylogenetically distant SARS-CoV-2 variants of concern in miceIrene González-Domínguez, Jose Luis Martínez, Stefan Slamanig, et al.
Frontiers in Immunology|April 1, 2025
Mucosal multivalent NDV-based vaccine provides cross-reactive immune responses against SARS-CoV-2 variants in animal modelsIrene González-Domínguez, Adam Abdeljawad, Tsoi Ying Lai, et al.
Nature Communications|October 28, 2021
A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responsesWeina Sun, Yonghong Liu, Fatima Amanat, et al.
Medrxiv : the Preprint Server for Health Sciences|September 28, 2021
Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 TrialPunnee Pitisuttithum, Viravarn Luvira, Saranath Lawpoolsri, et al.
Eclinicalmedicine|March 14, 2022
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trialPunnee Pitisuttithum, Viravarn Luvira, Saranath Lawpoolsri, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Biorxiv : the Preprint Server for Biology|August 9, 2020
A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccineWeina Sun, Stephen McCroskery, Wen-Chun Liu, et al.
Biorxiv : the Preprint Server for Biology|March 30, 2022
Trivalent NDV-HXP-S vaccine protects against phylogenetically distant SARS-CoV-2 variants of concern in miceIrene González-Domínguez, Jose Luis Martínez, Stefan Slamanig, et al.
Frontiers in Immunology|April 1, 2025
Mucosal multivalent NDV-based vaccine provides cross-reactive immune responses against SARS-CoV-2 variants in animal modelsIrene González-Domínguez, Adam Abdeljawad, Tsoi Ying Lai, et al.
Nature Communications|October 28, 2021
A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responsesWeina Sun, Yonghong Liu, Fatima Amanat, et al.
Medrxiv : the Preprint Server for Health Sciences|September 28, 2021
Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 TrialPunnee Pitisuttithum, Viravarn Luvira, Saranath Lawpoolsri, et al.
Eclinicalmedicine|March 14, 2022
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trialPunnee Pitisuttithum, Viravarn Luvira, Saranath Lawpoolsri, et al.
Pageof 2